|
Oct. 30, 2024 |
|
|
Oct. 06, 2025 |
|
|
jRCT2041240115 |
33-506 :Special Drug Use-Results Survey of OPDIVO (Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma) |
|
33-506 :Special Drug Use-Results Survey of OPDIVO |
Nakao Takafumi |
||
Ono Pharmaceutical Co.,LTD |
||
1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan |
||
+81-6-6222-5501 |
||
pms_contact_ml@ono-pharma.com |
||
Nakao Takafumi |
||
Ono Pharmaceutical Co.,LTD |
||
1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan |
||
+81-6-6222-5501 |
||
pms_contact_ml@ono-pharma.com |
Recruiting |
May. 13, 2024 |
||
| July. 23, 2024 | ||
| 30 | ||
Observational |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
other |
||
Patients with unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma, who have recieved OPDIVO for the first time |
||
Patients who have received OPDIVO previously |
||
| No limit | ||
| No limit | ||
Both |
||
Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma |
||
'[Efficacy] |
||
| Ono Pharmaceutical Co.,LTD |
| Not being included in the items required by GPSP Ordinance, a central IRB is not in place. The study is planned to conduct an IRB at the study site as needed. | |
| none, Ishikawa | |
July. 10, 2024 |
No |
none |